pbi12089-sup-0001-SuppinfoS1.tifimage/tif646KFigure S1 Purification of the plant-produced HPV antigens.
pbi12089-sup-0002-SuppinfoS2.tifimage/tif542KFigure S2 Enrichment of the plant-produced L1 and L1/L2 vaccine antigens.
pbi12089-sup-0003-SuppinfoS3.tifimage/tif946KFigure S3 Western blot quantification of HPV antigens using the commercial vaccine Cervarix.
pbi12089-sup-0004-SuppinfoS4.tifimage/tif1136KFigure S4 Electron microscopy of purified HPV-16, HPV-18, HPV-45 and HPV-52 pseudovirions (PsVs).
pbi12089-sup-0005-SuppinfoS5.tifimage/tif445KFigure S5 HPV-52 PsV neutralisation assay for (a) L1/L2 (108–120), in comparison with HPV-16 L1, the current antigen used in HPV prophylactic vaccines, and (b) H52.C1 and H52.D11 MAb (both +ve neutralisation controls).
pbi12089-sup-0006-SuppinfoS6.tifimage/tif479KFigure S6 Plasmids used for plant expression.
pbi12089-sup-0007-Legend.docxWord document15K 

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.